A new malaria vaccine developed by researchers at Oxford University and partners is the first to have achieved the World Health Organization (WHO) roadmap efficacy goal of 75 percent, marking a turning point for a potential malaria vaccine to make it into the arms of those that need it in the near future.
Malaria remains a daunting global health concern. Figures by the WHO have shown that in 2019 alone 229 million cases were reported around to world, with an estimated 409,000 deaths due to the mosquito-borne infectious disease. Children under the age of 5 are the most vulnerable, accounting for 67 percent of the global deaths in 2019 alone.